Skip to main content
. 2022 Jan 18;14(3):427. doi: 10.3390/nu14030427

Table 2.

Anthropometry data for all trial participants.

Active Placebo
Baseline Month 3 Month 6 Baseline Month 3 Month 6
WC (cm) 101.1 ± 9.9 98.5 ± 10.5 # 97.2 ± 10.7 *# 103.4 ± 11.0 101.3 ± 11.4 # 101.7 ± 11.7 #
HC (cm) 113.4 ± 6.9 111.0 ± 7.5 # 110.1 ± 7.5 *# 115.6 ± 7.2 113.6 ± 6.7 # 113.5 ± 7.2 #
Weight (kg) 88.4 ± 11.2 85.5 ± 11.5 # 84.7 ± 11.7 *# 90.8 ± 13.8 89.0 ± 14.1 # 88.8 ± 14.5 #
Weight loss (%) −3.2 ± 3.7 # −4.2 ± 5.0 *# −2.1 ± 3.3 −2.2 ± 4.2 #
BMI (kg/m2) 29.5 ± 1.6 28.6 ± 2.0 # 28.3 ± 2.2 *# 29.4 ± 1.4 28.9 ± 1.7 # 28.8 ± 1.9 #
Lean Mass (kg) 54.0 ± 11.3 52.5 ± 10.1 52.4 ± 10.2 # 56.1 ± 13.0 55.4 ± 12.8 55.6 ± 13.2 #
FM (kg) 32.1 ± 7.2 30.6 ± 6.4 *# 29.7 ± 6.7 *# 33.1 ± 7.5 31.8 ± 8.0 # 31.2 ± 8.2 #
FM Arm (kg) 3.9 ± 1.1 3.7 ± 0.9 3.6 ± 0.9 # 3.7 ± 1.0 3.6 ± 1.0 3.5 ± 1.0 #
FM Leg (kg) 11.9 ± 3.3 11.4 ± 3.2 11.4 ± 3.8 # 12.2 ± 3.8 11.5 ± 4.0 11.3 ± 3.6 #
FM abdominal (trunk) (kg) 15.9 ± 3.3 14.6 ± 3.5 *# 14.1 ± 3.5 *# 16.3 ± 4.1 15.6 ± 4.4 # 15.3 ± 4.4 #
Android Fat (kg) 3.6 ± 1.8 2.7 ± 1.0 # 2.6 ± 1.0 # 4.0 ± 2.1 3.1 ± 1.4 3.0 ± 1.4 #
Gynoid Fat (kg) 7.0 ± 3.8 5.2 ± 1.5 # 5.1 ± 1.5 # 7.7 ± 4.0 5.9 ± 2.8 # 5.9 ± 2.8 #
Visceral Fat (g) 632.9 ± 223.5 588.6 ± 245.3 # 554.2 ± 232.4 *# 632.8 ± 249.6 581.5 ± 256.6 # 575.8 ± 254.9 #
Visceral Fat Area (cm2) 131.4 ± 46.4 122.0 ± 51.0 115.6 ± 47.4 # 131.5 ± 52.0 120.1 ± 53.1 118.6 ± 52.6 #
Subcutaneous Fat (kg) 15.2 ± 3.1 14.0 ± 3.4 # 13.5 ± 3.4 *# 15.7 ± 3.9 15.0 ± 4.2 # 14.7 ± 4.3 #

# Indicated significant decrease from baseline within group (p < 0.05); * indicates significant difference between groups (p < 0.05) in ITT analysis; (DEXA measures baseline placebo n = 69, active n = 62; 3- and 6-month placebo n = 56, active n = 46). WC = waist circumference; HC = hip circumference; BMI = body mass index; FM = fat mass.